Delivery Order SPE2DB22D1106-SPE2DB25FEKL5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gvoke HypoPen 2-pack auto-injectors (1 mg/0.2 mL) with a ceiling value of $2,832.92. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,501.51 to AmerisourceBergen Drug Corp for Gvoke HypoPen auto-injectors (1 mg/0.2 mL, 2-pack). This competitive award, issued on July 28, 2025, represents a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement, indicating open competition among eligible...
- The Defense Logistics Agency awarded a $1,734.47 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gvoke HypoPen auto-injectors (1 mg/0.2 ml, 2-pack). The contract, which represents a non-competitive delivery order under an existing indefinite delivery vehicle, will be fulfilled from the vendor's Conshohocken, Pennsylvania location with a completion date of September 10, 2025. This award is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,981.46 to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Gvoke HypoPen 2-pack (1 mg/0.2 mL) auto-injectors. The contract, which is not set aside and was competitively awarded, specifies a firm fixed price structure with an ultimate completion date of June 2, 2025. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $5,028.47 to AmerisourceBergen Drug Corp for the supply of Gvoke HypoPen 2-pack auto-injectors (0.5mg/0.1ml) on August 29, 2025, with an ultimate completion date of September 2, 2025. This non-competitive delivery order represents a firm fixed price transaction and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The product is a glucagon emergency injection device used for treating severe...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of GVOKE HypopenPen auto-injectors (2-pack, 1 mg/0.2 ml formulation) with a ceiling value of $1,456.72. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, and performance will be executed from the company's location in Conshohocken, Pennsylvania. The order is set for ultimate completion by August 19, 2025. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,519.71 to AmerisourceBergen Drug Corp for Gvoke HypoPen 2-Pack 1 mg/0.2 ml auto-injectors. This firm fixed-price, competitively awarded contract was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order operates as a child contract under AmerisourceBergen's existing indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,087.62 to AmerisourceBergen Drug Corp for GVOKE HypoPen 2-Pack 1 mg/0.2 ml auto-injectors. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The contract involves delivery to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. No set-aside provisions were utilized for this award. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for GVOKE HypopenTM auto-injector units (2-pack, 1 mg/0.2 mL formulation) with a ceiling value of $19,036.29. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The contract specifies performance at the contractor's Conshohocken,...
- The Defense Logistics Agency awarded a $2,522.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for one package of Gvoke HypoGel 1 mg/0.2 mL auto-injector. The order is set to be completed by August 18, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's broader federal pharmaceutical supply portfolio. This...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEKL5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Gvoke HypoPen 2-pack auto-injectors (1 mg/0.2 mL) with a ceiling value of $16,139.59. This is a firm fixed price delivery order with an ultimate completion date of April 25, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitive award. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp serves as a prime pharmaceutical distributor for the Defense Logistics Agency's Medical Supply Chain, providing a broad portfolio of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare systems. The Gvoke HypoPen is a critical emergency medication used to treat severe hypoglycemia, reflecting the company's role in supplying essential therapeutic medications across multiple medical domains to defense and federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 4/24/25 |